Bispecific antibodies (BsAbs) are renowned for their capabilities of recognizing or binding to two or more antigens simultaneously, having focused great attention on immunotherapy in recent years. A diversity of BsAbs have been developed and pushed into clinical trials for the treatment of various human diseases, such as tumors, autoimmune diseases, hematological diseases, infections, etc. As a kind of engineered antibody, a diverse range of BsAb types have been created, such as tandem scFv, bibody, and single chain IgGs, among which biparatopic antibody is a special type that refers in particular to BsAb engineered to bind to two distinct epitopes on the same target. Biparatopic antibody has an enhanced binding to the target via antigen crosslinking and aggregation, exhibiting superior activities than each single paratope.
Fig. 1 Biparatopic antibody and its screening.1
Creative Biolabs has successfully finished hundreds of BsAb projects, covering from recombinant bsAb production and validation to one-stop BsAb development based on customers' specific needs. We have won a good reputation for delivering high-quality BsAb products and customized BsAb services. Benefiting from abundant BsAb project experience and a powerful technology platform, we are now launching biparatopic antibody development services to facilitate the advancement of BsAb drugs.
We can provide rapid recombinant biparatopic antibody production and purification service if you have a definite sequence of antibody variable regions. Otherwise, we also offer one-stop or tailored biparatopic antibody development services according to your demands, including but not limited to:
Title: An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Journal: Nature Communications
Abstract: The scientists engineered an anti-HER2 (human epidermal growth factor receptor type 2) IgG1 biparatopic antibody, with the ability to bind to ECD4 and ECD2 of HER2. Assays showed that this HER2 biparatopic antibody had enhanced in vitro complement-dependent cytotoxicity against HER2-expressing tumor cells and a better in vivo antitumor activity in the xenograft tumor model.
Fig. 2 Anti-HER2 biparatopic antibody and its binding saturation.2
Title: Bp-Bs, a novel T-cell engaging bispecific antibody with biparatopic Her2 binding, has potent anti-tumor activities
Journal: Molecular Therapy-Oncolytics
Abstract: The author constructed a new anti-HER2 bispecific antibody through the combination of two HER2 single-domain antibodies against two distinct epitopes on HER2 to an anti-CD3 Fab fragment. Comparative assays have been performed to evaluate the activities of the anti-HER2 bispecific antibody. The result indicated that the HER2 bispecific antibody had a higher affinity to HER2, a more potent T cell cytotoxicity, and a higher in vivo tumor inhibition activity than the HER2 bispecific antibody.
Fig. 3 Schematic diagram of HER2 bispecific antibody.3
Creative Biolabs has abundant project experience to offer sophisticated, canonical, and innovative BsAb, especially biparatopic antibody, development services tailored to customers' exact needs. Our technical staff are always ready online to provide professional and customized support and services. Any question or demand about bispecific antibody products and services, just feel free to contact us or directly send us an inquiry.
References
1. Bogen, Jan P., et al. "Expeditious generation of biparatopic common light chain antibodies via chicken immunization and yeast display screening." Frontiers in Immunology 11 (2020): 606878.
2. Weisser, Nina E., et al. "An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity." Nature Communications 14.1 (2023): 1394.
3. Liu, J., Wu, X., Lin, L., Pan, H., Wang, Y., Li, Y., ... & Wang, Z. (2019). Bp-Bs, a novel T-cell engaging bispecific antibody with biparatopic Her2 binding, has potent anti-tumor activities. Molecular Therapy-Oncolytics, 14, 66-73.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY
SERVICES
PRODUCTS
PLATFORMS
